文献速递淋巴瘤

慢性淋巴细胞白血病:2022年诊断与治疗更新

Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
PubMed 文献 · Am J Hematol · 2021-01-01

该综述更新了慢性淋巴细胞白血病(CLL)的诊断、预后与治疗。诊断基于血细胞计数、血涂片和免疫表型。治疗仅适用于有症状或晚期患者,推荐靶向药物如BCL2抑制剂联合奥滨尤妥珠单抗或BTK抑制剂单药。

要点

  • 诊断依赖血细胞计数、血涂片和免疫表型(CD5+克隆性B细胞)。
  • del(17p)或TP53突变提示对化疗免疫治疗抵抗,应选用靶向药物。
  • 复发时若无治疗间期超过3年可重复初始治疗,否则更换方案。

核心结论

  • CLL诊断基于血细胞计数、血涂片和免疫表型鉴定CD5+克隆性B细胞。
  • 治疗仅适用于有活动性症状或晚期Binet/Rai分期患者。
  • del(17p)或TP53突变患者对化疗抵抗,应使用靶向药物。

研究设计与样本

  • 综述,检索范围未在摘要中明确报告。

主要发现

  • CLL通常发生于老年患者,临床病程高度可变。
  • 白血病转化由特定基因组改变启动,干扰克隆B细胞增殖与凋亡调节。
  • CLL国际预后指数整合遗传、生物学和临床变量以识别不同风险组。

关键数值与推荐

  • 治疗指征:有活动性或症状性疾病,或晚期Binet/Rai分期。
  • 可选方案:BCL2抑制剂venetoclax联合obinutuzumab;BTK抑制剂(如ibrutinib、acalabrutinib)单药;或化学免疫治疗。
  • 复发时若治疗间期超过3年可重复初始治疗,否则更换方案。
  • del(17p)或TP53突变患者应接受靶向药物治疗。

临床怎么用

  • 通过血细胞计数、血涂片和免疫表型确诊CLL。
  • 根据症状和Binet/Rai分期决定是否启动治疗。
  • del(17p)或TP53突变患者避免化疗,优选靶向药物。
  • 复发时根据治疗间期决定重复或更换方案。

局限性

  • 摘要未报告检索范围、样本量或具体疗效数据。
  • 靶向药物联合方案及最佳序贯尚未确定。
  • BTK和BCL2抑制剂双耐药患者需要替代疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and of apoptosis in clonal B-cells. DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen as well as typical B-cell markers. PROGNOSIS AND STAGING: The clinical staging systems provide prognostic information by using the results of physical examination and blood counts. Various biological and genetic markers provide additional prognostic information. Deletions of the short arm of chromosome 17 (del[17p]) and/or mutations of the TP53 gene predict resistance to chemoimmunotherapy and a shorter time to progression with most targeted therapies. The CLL international prognostic index integrates genetic, biological, and clinical variables to identify distinct risk groups of patients with CLL. THERAPY: Only patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. When treatment is indicated, several therapeutic options exist: a combination of the B-cell lymphoma 2 (BCL2) inhibitor venetoclax with obinutuzumab, monotherapy with inhibitors of Bruton tyrosine kinase (BTK) such as ibrutinib and acalabrutinib, or chemoimmunotherapy. At relapse, the initial treatment may be repeated, if the treatment-free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using an alternative regimen. Patients with a del(17p) or TP53 mutation are usually resistant to chemotherapy and should, therefore, be treated with targeted agents. FUTURE CHALLENGES: Combinations of targeted agents are now being investigated to create efficient, potentially curative therapies of CLL with fixed duration. One of the most relevant questions currently addressed in clinical trials is the comparison of monotherapies with BTK inhibitors with fixed duration combination therapies. Moreover, the optimal sequencing of targeted therapies remains to be determined. Alternative therapies are needed for patients with BTK and BCL2 inhibitor double-refractory disease.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021. PMID: 34625994. doi:10.1002/ajh.26367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。